Cipla: Better positioned to grow and deal with tariff uncertainties
Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...
来自MSN11 个月
US FDA's 6 observations for Cipla's Patalganga unit drags firm's shares down 1.5%
Cipla's Patalganga plant manufactures active pharmaceutical ingredients (APIs), the key raw materials for medicines, as well as formulations. The US drug regulator had conducted a routine current ...
Reuters27 天
Tariffs should not dictate how Indian drugmakers do business, Cipla CEO says
MUMBAI/BENGALURU, Feb 28 (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's (CIPL.NS), opens ... will make to us... and will not justify relocating our ...
Mint27 天
Kotak Equities is optimistic on Indian pharma despite US tariff uncertainties; Sun Pharma ...
In light of uncertainties surrounding US tariffs on pharmaceuticals, Kotak Institutional Equities noted in a recent report that the most likely scenario (for both companies and investors ...